

AMGEN UK TAX STRATEGY STATEMENT

- We conduct business with honesty and integrity and in compliance with applicable laws and regulations. Our approach to UK tax planning is aligned with our business model, balancing the interests of our various stakeholders, including patients, customers, investors and the communities in which we operate. Any UK tax planning that we may engage in reflects the commercial and economic activities of our business and is in compliance with tax laws, regulations and relevant international standards (e.g. OECD Guidelines). Where tax law is unclear, we might seek professional advice on U.K. tax matters.
- Our Code of Conduct sets out standards of behaviour that every person conducting business for our company must follow. We comply with our responsibility to provide accurate and timely UK tax disclosures and filings. Our tax governance includes responsibility for UK tax matters by our European tax team with oversight by our global tax function that reports to the Chief Financial Officer. We have a set of policies and procedures as well as a formalised decision making process to ensure decisions are made at the appropriate level and supported by analysis of applicable tax laws and regulations. This helps to ensure tax risks are identified, controlled and reported. The Audit Committee of our Board regularly receives updates and provides oversight of the Company's financial reporting processes, including the Company's tax matters.
- Maintaining ethical and respectful relationships with government agencies, policy makers and other public officials including HMRC is an important element of how we do business. We work with HMRC to resolve all tax matters in a proactive and professional manner.

This published UK tax strategy has been approved by the Board of Directors for all UK based Amgen Group companies and has been prepared in accordance with our obligations under Paragraph 16(2) of Schedule 19 of the Finance Act 2016. It is effective for the year ending 31 December 2023.